TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Knowledge of healthy eating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Attitude of healthy eating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Eating behaviours
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Severity or occurrence of pancreatic fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Dilatation of the brachial artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent Change from Baseline in Fasting TG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cumulative incidence of stage 2 or higher breast cancer
Endpoint domain: Mortality/survival
Primary endpoint: Nature, frequency and severity of adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with vital signs abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with laboratory value abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects able to completely withdraw nasal decongestants after 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects who relapsed after withdrawal by follow-up 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in citrulline level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dysfunction at 10 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom bothersomeness at 10 weeks
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Short-term infection risk
Endpoint domain: Adverse events/effects
Primary endpoint: Near best corrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intermediate (80cm) best corrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Far best corrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Muscle strength - Handgrip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life - Short Form 36 (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of Refeeding syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of significant paravalvular leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Social Anxiety Scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: survival rates of patients with unicompartmental knee prosthesis
Endpoint domain: Mortality/survival
Primary endpoint: Radiographic objective disease response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Corticosteroid free remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: metabolic activity in the ACL graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: dynamic uptake rate of FDG in the ACL graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: BDNF serum levels variations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients achieving at least a 20% reduction from intraocular pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Whole-body fatty acid oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postoperative sensitivity in posterior teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIT-6 Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of time spent above CF 10 grams at Left superior pulmonary vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of time spent above CF 10 grams at Left middle pulmonary vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of time spent above CF 10 grams at Left inferior pulmonary vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of time spent above CF 10 grams at Right superior pulmonary vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of time spent above CF 10 grams at Right middle pulmonary vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Visual analog scale (VAS) addiction score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time Between Baseline Treatment and Recurrence of Active Disease
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase of cutaneous lower extremity perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: Incidence of intraoperative central venous line insertion
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative return of bowel function via flatus or passage of stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Patient-Rated Wrist Evaluation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction of egg excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression Free Survival for 6 months (PFS-6)
Endpoint domain: Mortality/survival
Primary endpoint: P-gp expression in blood samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Methotrexate concentration in blood samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in IPOS-Renal symptom assessment score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in KDQOL-SF 36 Quality of Life Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Difference between the number of documented advanced care planning between arms
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 3 dimensional gait analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pattern of injury on High Definition MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of beverage choices per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of fruit and vegetable servings per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VEP Amplitude at 15% Contrast
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: VEP Latency at 15% Contrast
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PERG Magnitude at 16 degree stimulus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of rise in hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With an Adverse Event (AE), Serious Adverse Event (SAE), or Death
Endpoint domain: Adverse events/effects
Primary endpoint: Evaluation of endocrine or metabolic conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Treatment emergent number of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum plasma concentration of niclosamide (µg/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Time Curve from predose until last detectable concentration of niclosamide (AUC0-last) [µg/ml*h]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conversion efficiency of b-C to retinol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of subjective pain threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Dopamine release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area under the LSR-Time Curve (AUC 0-43 days)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: major birth defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Perceived message effectiveness (PME)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perception of how discouraging the label is
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Correct identification of items high in added sugars
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Variation in hemoglobin rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in levels of hs-CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Greater Than 50% Reduction in Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HE4 and CA-125 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Reduction in Serum Lactate Dehydrogenase (LDH) Levels Within the First 4 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change From Baseline in Serum Lactate Dehydrogenase (LDH) Levels Over the Entire Treatment Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of arrhythmia or seizure
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical Global Impression (CGI) Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of Severe Hypoglycemia Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of episodes of desaturation during a feeding episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of episodes of bradycardia during a feeding episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of episodes of apnoea during a feeding episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of episodes of temperature instability during a feeding episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Successful Primary Placement of the Double Lumen Tube
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in FACT-Fatigue scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Number of Participants With Prolonged Air Leak (PAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of patients with rectal recurrence of endometriosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: DASH questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: PCS questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Wahler Physical Symptom Inventory
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: CESD questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Myotonometric Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients experiencing toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in oral microflora
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Montgomery Asberg Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Change in Esophageal Length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of cognitive behavioral therapy trial
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of recruitment and enrollment into cognitive behavioral therapy trial
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: total bleeding up to 48 hours of the operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: number of bags of red blood cells transfused up to 48 hours of the operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 7-day point prevalence cigarette abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Bleeding frequency in von Willebrand Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: uMRD in BM by flow cytometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major clinical events at one-year
Endpoint domain: Mortality/survival
Primary endpoint: 30-day event rate
Endpoint domain: Mortality/survival
Primary endpoint: 31-day to 12-month event rate
Endpoint domain: Mortality/survival
Primary endpoint: Improvement of irritable bowel syndrome symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Positive Psychotic Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Mood Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Achievement of symmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with treatment protocol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Toxicities graded according to the NCI CTC
Endpoint domain: Adverse events/effects
Primary endpoint: Calcineurin trough levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum creatinine peak level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Signal to background ratios of identified colonic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of dysplastic and cancerous lesions identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Insulin resistance (indices)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fasting insulin levels (µIU/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fasting glucose levels (mg/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Inflammatory response in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Pre-lens Tear Lipid Layer Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score change of PUQE scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Successful Weight Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Visual Analogue Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Universal Goniometer readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Neck Disability Index score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in brain metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of remote transmissions of data
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to CoVid19 symptoms relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with negative Clinical CoVid19 symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement and maintenance of PGA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement and maintenance of TLSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Subjective eczema control
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of estimated glomerular filtration rate (eGFR) decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Summary performance score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Frequency of cardiovascular and arterial thromboembolic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: decrease in the extent of brain white matter microglial activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Implant survivorship
Endpoint domain: Mortality/survival
Primary endpoint: Completion of daily self-report survey questions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Emergency surgery rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Steps Taken Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Swabs positive for enteric bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Treatment Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: doses required for induction of anaesthesia until loss of eyelash reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Study Drug-Related Adverse Events Grade 3 or Higher
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Study Drug-Related Immune-Related Adverse Events (IRAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Adverse Events (AEs) Corresponding to Retroviral Rebound Syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Intensity of thirst
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Discomfort of thirst
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Social Behavior
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Xerostomia related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in PaedQoR-15 scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Intra Ocular Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Teacher Attitudes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Strengths and Difficulties Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Pediatric Quality of Life Inventory
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Ultrasound tissue characterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute GVHD occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Acute GVHD grading
Endpoint domain: Adverse events/effects
Primary endpoint: Satisfactory imaging rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modified rankin scale (mRs) at 90 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of OHSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak serum E2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Corneal Nerve Fiber Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Acute Respiratory Infection necessitating workforce removal
Endpoint domain: Adverse events/effects
Primary endpoint: C-terminal Telopeptide of Collagen (CTx) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prediction probability Pk for consciousness vs unconsciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurologic outcome evaluated by cerebral performance category
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Patients With PSA Doubling Time >=3 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in International Restless Leg Syndrome (IRLS) rating scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Harms
Endpoint domain: Adverse events/effects
Primary endpoint: Financial Harms
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Overdiagnosis
Endpoint domain: Adverse events/effects
Primary endpoint: Psychosocial Harms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing